ConductScience.org, home

Library / Trial comparisons

Real TMS vs Sham TMS: deaths from any cause

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

Measures 6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNoteSource
Risk in group 1000.149wilsonClinicalTrials.gov
Risk in group 200.00000000000000001390.138wilsonClinicalTrials.gov
Risk difference, group 1 minus group 20-0.1380.149newcombe hybrid scoreClinicalTrials.gov
Risk ratio, group 1 over group 2loga group has no participants with the outcomeClinicalTrials.gov
Odds ratio, group 1 over group 2loga cell of the two-by-two table is zeroClinicalTrials.gov
Number needed to harmfrom the risk difference intervalthe two groups' risks are equalClinicalTrials.gov

Groups 2

Group 2 names the comparator: sham.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov codeSource
Group 1Real TMS
TMS will be administered using a 70-mm diameter air-cooled figure-of-8 coil and SuperRapid2 Magstim Stimulator. Repetitive pulses will be delivered to the right and dorsolateral left pre-frontal cortex (Brodmann area 46) using a frameless stereotactic navigation system and the subject's magnetic resonance imaging (MRI) in Brainsight software. Stimuli will be delivered at 20 Hz at 90% resting motor threshold (rMT) for 25 trains of 30 pulses per train, inter-train interval of 30 seconds for a total of 750 pulses per hemisphere. This dose and duration of repetitive TMS (rTMS) is based on physiological studies of healthy adults and treatment studies of cognition in PD and Alzheimer's disease. Side of first stimulation (left vs right hemisphere) will be counterbalanced across subjects.~Real TMS: real treatment
022EG000ClinicalTrials.gov
Group 2Sham TMSSham stimulation will be delivered using a sham coil fitted with electrodes to mimic both the auditory and somatic sensation of real TMS.~Sham TMS: placebo treatment024EG001ClinicalTrials.gov

Harm 2

FieldValueSource
What it countsTotal, all-cause mortalityClinicalTrials.gov
Time frameAdverse event data was collected throughout the study, i.e. 6 weeks.ClinicalTrials.gov

Trial 8

FieldValueSource
TitleCognitive Dysfunction in Parkinson's DiseaseClinicalTrials.gov
NCT numberNCT02346708ClinicalTrials.gov
PhasesNAClinicalTrials.gov
ConditionsParkinson's DiseaseClinicalTrials.gov
InterventionsReal TMS, Sham TMSClinicalTrials.gov
Lead sponsorUniversity of Colorado, DenverClinicalTrials.gov
Results first posted2020-12-09ClinicalTrials.gov
Results on ClinicalTrials.govhttps://clinicaltrials.gov/study/NCT02346708?tab=resultsClinicalTrials.gov

Source 4

FieldValueSource
Releasetrial-comparisons-2026-03-23-0.1.0ClinicalTrials.gov
Release manifest SHA-256f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57ClinicalTrials.gov
AACT copy2026-03-23ClinicalTrials.gov
Tables readoutcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquetClinicalTrials.gov

The same record as JSON

Release trial-comparisons-2026-03-23-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.